# TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

> **NCT04695327** · PHASE1 · COMPLETED · sponsor: **TILT Biotherapeutics Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** TILT-123

## Key facts

- **NCT ID:** NCT04695327
- **Lead sponsor:** TILT Biotherapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2025-09-03
- **Final completion:** 2025-09-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695327, "TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04695327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*